Finally, this study opens a path to a better understanding of the mutated FKRP causing dystroglycanopathies and should contribute to the future development of therapeutic strategies. This evidence concerns the gene FKRP and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.